FDA approves first-in-class treatment for rare adrenal tumors
The US FDA has approved Progenics Pharmaceuticals’ Adzera®, a first-in-class treatment for two rare adrenal tumors: pheochromocytoma and paraganglioma.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>